Palvella Therapeutics (NASDAQ:PVLA) Trading Down 7.9% – Should You Sell?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) shares dropped 7.9% on Wednesday . The company traded as low as $140.95 and last traded at $140.71. Approximately 103,392 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 286,451 shares. The stock had previously closed at $152.82.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Wall Street Zen downgraded Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday. Chardan Capital reissued a “buy” rating and issued a $240.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Stephens reissued an “overweight” rating and set a $220.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Finally, HC Wainwright boosted their price objective on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Palvella Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Stock Performance

The stock has a market capitalization of $1.96 billion, a PE ratio of -32.78 and a beta of -0.15. The company has a 50 day moving average of $119.85 and a two-hundred day moving average of $111.05.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). As a group, research analysts predict that Palvella Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the transaction, the chief operating officer owned 2,154 shares in the company, valued at approximately $238,512.42. This represents a 66.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.20% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

Institutional investors have recently bought and sold shares of the company. KBC Group NV acquired a new stake in Palvella Therapeutics during the 1st quarter worth $28,000. Group One Trading LLC increased its holdings in shares of Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after buying an additional 200 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Palvella Therapeutics in the third quarter valued at $36,000. JPMorgan Chase & Co. raised its holdings in Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after buying an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Palvella Therapeutics in the 2nd quarter worth approximately $85,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.